tbuckley/cabot-search huggingface dataset:
Analysis of high-dose methotrexate with rituximab versus other treatment regimens for primary central nervous system (CNS) lymphoma.
Authors: Scott Michael Lindhorst, Frances McSherry, Annick Desjardins, Henry S. Friedman, Katherine B. Peters
Journal: Journal of Clinical Oncology (2013)

2090 Background: The most effective and least toxic treatment regimen for primary CNS lymphoma is a matter of debate. Most current regimens utilize various doses of high-dose methotrexate combined with other agents. The utility of deferred radiation is also under study. Methods: We evaluated 28 patients with primary CNS lymphoma treated with methotrexate 3.5 g/m 2 and rituximab, as well as alternative regimens. Median, 12-month, and 24-month survival were compared for the various treatment regimens, as well as for patients who received radiation and those who did not. Results: Survival rates were significantly better in the methotrexate-rituximab treatment cohort than the other regimens examined (Log-Rank p-value 0.0437). 12-month survival for the methotrexate-rituximab cohort was 72.7% (95% CI, 37.1% to 90.3%) versus the alternative treatment cohort 12-month survival of 49.4% (95% CI, 23.7% to 70.8%). 24-month survival for the methotrexate-rituximab cohort was 72.7% (95% CI, 37.1% to 90.3%) versus the alternative treatment cohort 24-month survival of 39.5% (95% CI, 14.9% to 63.6%). Median survival for the alternative treatment cohort was 11 months (95% CI, 2.2 to 28.6), while the median survival for the methotrexate-rituximab regimen was not reached. Stratified by radiation, survival rates were significantly better in the radiation cohort than the cohort without radiation (Log-Rank p-value 0.0040). 12-month survival for the radiation cohort was 90% (95% CI, 47.3% to 98.5%) versus the cohort without radiation 12-month survival of 40.5% (95% CI, 17.7% to 62.3%). 24-month survival for the radiation cohort was 90% (95% CI, 47.3% to 98.5%) versus the cohort without radiation 24-month survival of 33.7% (95% CI, 12.9% to 56.1%). Median follow-up for all patients was 21.5 months (95% CI, 16 to 42.1). Conclusions: The combination of methotrexate at 3.5 g/m 2 with rituximab is a valid treatment regimen for primary CNS lymphoma. Patients may be spared toxicity by using a methotrexate dose of 3.5 g/m 2 rather than 8 g/m 2 . The addition of radiation provided a significant survival advantage in this observational study, however, radiation deferred until progression may be a viable alternative.
Sixty seconds on . . . brushing teeth
Authors: Elisabeth Mahase
Journal: BMJ (2019)

Well done, but the government is concerned that many children aren’t, which is leading to thousands of tooth extractions, sometimes even for those under 5 years old.1

No, the government seems to be switching its focus for public health improvement to teachers. According to a report in the Sun, 2 it might suggest toothbrushes and toothpaste are placed in …
Task Force to Prevent Veteran Suicides
Authors: Rita Rubin
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Socially interested, or socially sophisticated? On mutual social influence in autism
Authors: Baudouin Forgeot d'Arc, Isabelle Soulières
Journal: Behavioral and Brain Sciences (2019)

Abstract A lower tendency to influence and be influenced by their social environment seems almost self-evident in autism. However, a closer look at differences and similarities between autistic and non-autistic individuals suggests that some basic mechanisms involved in social influence might be intact in autism, whereas atypical responses point to differences in more sophisticated recursive social strategies, such as reputation management.
For Mortality, Busting the Myth of 10 000 Steps per Day
Authors: Jennifer Abbasi
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Progesterone and Early Pregnancy Bleeding
Authors: Anita Slomski
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DNA Methylation as a Robust Classifier of Epithelial Ovarian Cancer
Authors: Charles A. Ishak, Stephanie Lheureux, Daniel D. De Carvalho
Journal: Clinical Cancer Research (2019)

Epithelial ovarian cancers (EOC) can be defined across different histologic subtypes by specific DNA methylation profiles which correlate with outcome. Identification of distinct EOC methylation subgroups emphasizes the role of epigenetic remodeling to establish unique EOC etiology during transformation, and harbors the potential to direct personalized medicine and patient care.See related article by Bodelon et al., p. 5937.
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer
Authors: Julien Taieb, Andreas Jung, Andrea Sartore-Bianchi, Marc Peeters, Jenny Seligmann, Aziz Zaanan, Peter Burdon, Clara Montagut, Pierre Laurent-Puig
Journal: Drugs (2019)

The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to important improvements in patient outcomes. However, it is still necessary to increase individualisation of treatments based on tumour genetic profiles to optimise efficacy, while minimising toxicity. As such, there is currently great focus on the discovery and validation of further biomarkers in mCRC, with many new potential prognostic and predictive markers being identified alongside developments in patient molecular profiling technologies. Here, we review data for validated and emerging biomarkers impacting treatment strategies in mCRC. We completed a structured literature search of the PubMed database to identify relevant publications, limiting for English-language publications published between 1 January 2014 and 11 July 2018. In addition, we performed a manual search of the key general oncology and CRC-focused congresses to identify abstracts reporting emerging mCRC biomarker data, and of ClinicalTrials.gov to identify ongoing clinical trials investigating emerging biomarkers in mCRC and/or molecular-guided clinical trials. There is solid evidence supporting the use of BRAF status as a prognostic biomarker and DYPD, UGT1A1, RAS, and microsatellite instability as predictive biomarkers in mCRC. There are a number of emerging biomarkers that may prove to be clinically relevant in the future to have prognostic (HPP1 methylation), predictive (HER3, microRNAs, anti-angiogenic markers, and CRC intrinsic subtypes), or both prognostic and predictive values (HER2, CpG island methylator phenotype, tumour mutational load, gene fusions, and consensus molecular subtypes). As such, new biomarker-led treatment strategies in addition to anti-epidermal growth factor receptor and anti-angiogenetic treatments are being explored. Biomarkers that are not recommended to be tested in clinical practice or are unlikely to be imminently clinically relevant for mCRC include thymidylate transferase, ERCC1, PIK3CA, and PTEN. We highlight the clinical utility of existing and emerging biomarkers in mCRC and provide recommended treatment strategies according to the biomarker status. An update on ongoing molecular-guided clinical trials is also provided.
Frequency of Anti-PF4/Heparin Antibodies in Patients Treated with Extra-Corporeal Membrane Oxygenation and Detection By Sensitized Serotonin Release Assay of Pathogenic Heparin-Induced Thrombocytopenia Antibodies
Authors: Caroline Vayne, Marc-Antoine May, Thierry Bourguignon, Eric Lemoine, Eve-Anne Guéry, Jérôme Rollin, Yves Gruel, Claire Pouplard
Journal: Blood (2018)
NIH Bayesian Score As a Stratification Tool in Sickle Cell Disease - Results from a Single Center Cohort in Brazil
Authors: Guilherme Henrique Hencklain Fonseca, Lutu Ima Viana da Graca, Rogerio Souza, Liliana Mitie Suganuma, Vanderson Rocha, Sandra Fatima Gualandro
Journal: Blood (2017)
Active <i>c</i>-Src has prognostic and therapeutic value in ER-negative breast cancer
Authors: A. Arnaout, L. Yang, C. Holloway, N. Steven, P. Sun, H. Kahn
Journal: Journal of Clinical Oncology (2006)

10063 Background: Approximately 33% of newly diagnosed breast cancers lack ER and these tend to have a worse prognosis as compared to ER-positive breast cancers. Therapeutic options are limited as they are not responsive to antihormonal therapy and often develop resistance to chemotherapies. We have recently shown that activation of the nonreceptor tyrosine kinase protein c-Src leads to the accelerated ER degradation in ER-negative breast cancers. This study performs an immunohistochemical analysis of activated c-Src in a large cohort of primary human breast carcinomas to a) assess its prognostic significance and b) correlate its relationship to the ER status of breast cancers. Methods: A total of 916 patients with breast cancer diagnosed between 1987 and 1997 had clinicopathological data and paraffin-embedded tumor tissues for the study. Tissue microarrays were constructed. A four point scoring system based on immunostaining intensity was used to grade the levels of active phosphorylated c-Src. Grading was done by one pathologist. Statistical analysis was used to assess the prognostic significance of activated c-Src and its relationship to other prognostic variables. Results: Median follow-up was 7.31 years. Active c-Src grade was inversely correlated with ER status (p=0.004) and predicted for treatment with chemotherapy (p=0.002) and lack of treatment with Tamoxifen (p=0.007). Patients with greater levels of c-Src tended to be younger (p=0.004) and had higher Bloom Richardson scores for their tumors (p=0.004). Higher levels of c-Src also predicted for for shorter timing to distant recurrence (p=0.01) and shorter timing to death (p=0.04). There was a trend towards a shorter timing to regional recurrence with higher levels of c-Src but the relationship was not statistically significant (p=0.08). Conclusion: This study supports the hypothesis that the presence of active, phosphorylated c-Src contributes to the development of ER-negative status in breast cancers. The presence of c-Src also is associated with other poor prognostic factors and contributes to a worse prognostic outcome. This study suggests that c-Src inhibitors may be a novel therapeutic strategy for the treatment of ER-negative breast cancers. No significant financial relationships to disclose.
Multifunctional scaffolds for facile implantation, spontaneous fixation, and accelerated long bone regeneration in rodents
Authors: Ben Zhang, Jordan D. Skelly, Jacob R. Maalouf, David C. Ayers, Jie Song
Journal: Science Translational Medicine (2019)

Self-stiffening, macroporous, shape-memory scaffolds delivering a low dose of osteogenic factors accelerate segmental long bone regeneration in rats.
Differential Variation Analysis Enables Detection of Tumor Heterogeneity Using Single-Cell RNA-Sequencing Data
Authors: Emily F. Davis-Marcisak, Thomas D. Sherman, Pranay Orugunta, Genevieve L. Stein-O'Brien, Sidharth V. Puram, Evanthia T. Roussos Torres, Alexander C. Hopkins, Elizabeth M. Jaffee, Alexander V. Favorov, Bahman Afsari, Loyal A. Goff, Elana J. Fertig
Journal: Cancer Research (2019)

Abstract Tumor heterogeneity provides a complex challenge to cancer treatment and is a critical component of therapeutic response, disease recurrence, and patient survival. Single-cell RNA-sequencing (scRNA-seq) technologies have revealed the prevalence of intratumor and intertumor heterogeneity. Computational techniques are essential to quantify the differences in variation of these profiles between distinct cell types, tumor subtypes, and patients to fully characterize intratumor and intertumor molecular heterogeneity. In this study, we adapted our algorithm for pathway dysregulation, Expression Variation Analysis (EVA), to perform multivariate statistical analyses of differential variation of expression in gene sets for scRNA-seq. EVA has high sensitivity and specificity to detect pathways with true differential heterogeneity in simulated data. EVA was applied to several public domain scRNA-seq tumor datasets to quantify the landscape of tumor heterogeneity in several key applications in cancer genomics such as immunogenicity, metastasis, and cancer subtypes. Immune pathway heterogeneity of hematopoietic cell populations in breast tumors corresponded to the amount of diversity present in the T-cell repertoire of each individual. Cells from head and neck squamous cell carcinoma (HNSCC) primary tumors had significantly more heterogeneity across pathways than cells from metastases, consistent with a model of clonal outgrowth. Moreover, there were dramatic differences in pathway dysregulation across HNSCC basal primary tumors. Within the basal primary tumors, there was increased immune dysregulation in individuals with a high proportion of fibroblasts present in the tumor microenvironment. These results demonstrate the broad utility of EVA to quantify intertumor and intratumor heterogeneity from scRNA-seq data without reliance on low-dimensional visualization. Significance: This study presents a robust statistical algorithm for evaluating gene expression heterogeneity within pathways or gene sets in single-cell RNA-seq data
Chronic dermatophytosis in lamellar ichthyosis: relevance of a T-helper 2-type immune response to Trichophyton rubrum
Authors: R.J. Ludwig, J.A. Woodfolk, M. Grundmann-Kollmann, R. Enzensberger, U. Runne, T.A.E. Platts-Mills, R. Kaufmann, T.M. Zollner
Journal: British Journal of Dermatology (2008)

British Journal of DermatologyVolume 145, Issue 3 p. 518-521 Chronic dermatophytosis in lamellar ichthyosis: relevance of a T-helper 2-type immune response to Trichophyton rubrum R.J. Ludwig, R.J. Ludwig Departments of Dermatology andSearch for more papers by this authorJ.A. Woodfolk, J.A. Woodfolk Asthma and Allergic Diseases Center, University of Virginia, Charlottesville, VA, U.S.A. Correspondence: Thomas M.Zollner. E-mail: Zollner@em.uni-frankfurt.deSearch for more papers by this authorM. Grundmann-Kollmann, M. Grundmann-Kollmann Departments of Dermatology andSearch for more papers by this authorR. Enzensberger, R. Enzensberger Microbiology, Johann Wolfgang Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, GermanySearch for more papers by this authorU. Runne, U. Runne Departments of Dermatology andSearch for more papers by this authorT.A.E. Platts-Mills, T.A.E. Platts-Mills Departments of Dermatology andSearch for more papers by this authorR. Kaufmann, R. Kaufmann Departments of Dermatology andSearch for more papers by this authorT.M. Zollner, T.M. Zollner Departments of Dermatology andSearch for more papers by this author R.J. Ludwig, R.J. Ludwig Departments of Dermatology andSearch for more papers by this authorJ.A. Woodfolk, J.A. Woodfolk Asthma and Allergic Diseases Center, University of Virginia, Charlottesville, VA, U.S.A. Correspondence: Thomas M.Zollner. E-mail: Zollner@em.uni-frankfurt.deSearch for more papers by this authorM. Grundmann-Kollmann, M. Grundmann-Kollmann Departments of Dermatology andSearch for more papers by this authorR. Enzensberger, R. Enzensberger Microbiology, Johann Wolfgang Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, GermanySearch for more papers by this authorU. Runne, U. Runne Departments of Dermatology andSearch for more papers by this authorT.A.E. Platts-Mills, T.A.E. Platts-Mills Departments of Dermatology andSearch for more papers by this authorR. Kaufmann, R. Kaufmann Departments of Dermatology andSearch for more papers by this authorT.M. Zollner, T.M. Zollner Departments of Dermatology andSearch for more papers by this author First published: 18 July 2008 https://doi.org/10.1111/j.1365-2133.2001.04390.xCitations: 11Read the full textAbout ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article.Citing Literature Volume145, Issue3September 2001Pages 518-521 RelatedInformation
Abstract 18599: Clinical Assessment of Hemodynamic Profiles Predict Readmission and Mortality in Diastolic Heart Failure Patients
Authors: Mohammed Siddiqui, Salpy V Pamboukian, Jose A Tallaj, Michael Falola, Sula Mazimba
Journal: Circulation (2015)

Background: Reducing 30 day readmission rates for patients with heart failure (HF) has been a recent focus of lowering health care expenditures. Hemodynamic profiles (HP) have been associated with clinical outcomes in chronic systolic HF. The relationship of HP to outcomes in acute decompensated diastolic HF (DHF) has not been defined. Methods: This case-control study of 1892 DHF patients discharged alive from an academic hospital between 2002-2012 with left ventricular function greater or equal to 45% were categorized into 4 groups: Profile A, no evidence of congestion and hypoperfusion (dry-warm); Profile B, congestion with adequate perfusion (wet-warm); Profile C, congestion with hypoperfusion (wet-cold); and Profile L, hypoperfusion without congestion (dry-cold). All cause readmissions at 30 days and 1 year and mortality at 30 days and 1 year were examined. Statistical analysis using multivariable Cox Proportional hazard model was performed adjusting for demographic, clinical, care and hospital characteristics. Results: Of the 1892 patients, 1196 (63%) were females; mean age was 68 (±14) years. There were 724(38%), 1000 (53%), 88(5%) and 80 (4%) patients in the hemodynamic profiles A, B, C and L respectively. Profiles B and C were associated with an increased risk for 30-day all-cause HF readmission compared to profiles A and L: Hazard ratio (HR) [1.38 (95% C.I 1.17-1.61)], [1.39 (95% C.I 1.18-1.62)] for B and C profiles respectively. Profiles C and L were associated with increased mortality at 1 year: HR [1.46 (95% CI 1.06-1.89)] and [1.31 (95% CI 1.01-1.64)] for A and L profiles respectively (Table). Conclusions: Clinical assessment of HP can help identify DHF patients at increased risk of readmission and mortality, similar to systolic heart failure patients.